Drug Injury Watch: 2012 FDA Report On Beyaz Points Out That Younger Women and Girls Are Most At-Risk For Blood Clots

Approved By FDA In 2010, There Has Been No Study Done Yet Regarding Beyaz Safety -- Despite Significant Number Of Beyaz Adverse Event Reports

(Posted by Tom Lamb at www.DrugInjuryWatch.com on August 31, 2012)

Excerpt: This new FDA report also informs us that the Adverse Event Reporting System (AERS) database contained 467 reports for Beyaz made during the period September 2010 to May 1, 2012. It is commonly recognized that serious side effects are "under-reported" to this FDA voluntary reporting program, with some estimates being that only 1% to 10% of such adverse reactions / incidents are the subject of an FDA MedWatch Report that is put into the AERS database.

[Read this article in full at original source]

Earlier DRSP Birth Control Pills articles by Tom Lamb on the Drug Injury Watch blog:

Bayer Settlements: Gianvi / Ocella / Yasmin / YAZ: July 2012 Update On Drug Injury Lawsuits Filed To Date

Medical Study Finds Link Between YAZ / Yasmin And Irritable Bowel Syndrome (IBS) Coming From Drospirenone (DRSP) Progestin

Bayer Settlements For YAZ / Yasmin Lawsuits Involving Blood Clot Side Effects Like Deep Vein Thrombosis And Pulmonary Embolism

April 2012 Yasmin / YAZ Label Change: FDA Warns About Increased Risk Of Blood Clots Possible Due To Drospirenone

YAZ / Yasmin Litigation Update: 11,300 Lawsuits Have Been Served Upon Bayer As Of February 1, 2012

Attorney Tom Lamb represents people in personal injury and wrongful death cases involving unsafe prescription drugs or medication errors. The above article was posted originally on his blog, **Drug Injury Watch** – with live links and readers' Comments.
http://www.DrugInjuryWatch.com